Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/Bc7c9798e56a5d56fa44609f32988cf9b> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- Bc7c9798e56a5d56fa44609f32988cf9b NCIT_P378 "CDISC-GLOSS" @default.
- Bc7c9798e56a5d56fa44609f32988cf9b type Axiom @default.
- Bc7c9798e56a5d56fa44609f32988cf9b annotatedProperty NCIT_P325 @default.
- Bc7c9798e56a5d56fa44609f32988cf9b annotatedSource NCIT_C49688 @default.
- Bc7c9798e56a5d56fa44609f32988cf9b annotatedTarget "Later Phase 2 trials, in transition to Phase 3, where the study populations more closely reflect the population, dosage, and condition for intended use. [Clarification of FDA Guidance for industry end of Phase 2a meetings, September 2009; Discussion in Peter B. Gilbert. SOME DESIGN ISSUES IN PHASE 2B VERSUS PHASE 3 PREVENTION TRIALS FOR TESTING EFFICACY OF PRODUCTS OR CONCEPTS. Stat Med. 2010 May 10; 29(10): 1061-1071.] See also phase, phase 2, phase 2a." @default.